Status:
COMPLETED
Carvedilol + VSL#3 Versus Endoscopic Variceal Ligation for Primary Prophylaxis of Esophageal Variceal Bleeding in Cirrhotic Patients Non Responder to Carvedilol.
Lead Sponsor:
Institute of Liver and Biliary Sciences, India
Conditions:
Cirrhosis
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Patients of cirrhosis will be enrolled who have large esophageal varices, which have never bled. After successful screening baseline hepatic venous pressure gradient (HVPG) will be measured. Tablet ca...
Eligibility Criteria
Inclusion
- Patients of cirrhosis with portal hypertension aged 18 to 75 years who have large esophageal varices with or without red color signs and have not bled previously.
Exclusion
- Any contra-indication to beta-blockers
- Coagulopathy with INR \>1.8 at the time of enrollment
- Any Endoscopic Variceal Ligation or sclerotherapy within last 3 months
- Any past history of surgery for portal hypertension
- Significant cardio or pulmonary co-morbidity
- Any malignancy
- Refusal to participate in the study
Key Trial Info
Start Date :
December 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2015
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01196481
Start Date
December 1 2012
End Date
August 1 2015
Last Update
May 15 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Liver & Biliary Sciences (ILBS)
New Delhi, National Capital Territory of Delhi, India, 110 070